A specific vaccine made by the Walter Reed Army Research Institute began clinical testing Tuesday, and Army researchers hope it can fight the SARS-COV-2 strain, the new coronavirus that causes it. COVID-19
A vaccine called a spike ferritin nanoparticle, or SpFN, can help fight Other coronaviruses, which are a group of related RNA viruses that often cause respiratory-related diseases in mammals.
Army researchers have tracked down the threat posed by the novel coronavirus before the outbreak, according to Kayvon Modjarrad, director of Emerging Infectious Diseases at Walter Reed. A few years ago
“That’s why we need a vaccine like this one that has the potential to provide broad-spectrum and proactive protection against multiple strains and strains of the coronavirus,” Modjarrad said in a statement announcing the SpFN test.
The Department of Defense has more than 271,000 COVID-19 infections, of which 3,814 hospitalizations and 332 deaths, twenty-four of them are service members, and 11 are those. Depend
The vaccines produced by Pfizer and Moderna are approved under license for emergency use by the U.S. Food and Drug Administration and are available to the Armed Forces.
The Pentagon has made vaccination a readiness problem so that military operations can return to pre-epidemic norms. Despite the difficulty of lobbying forces for voluntary vaccinations early, vaccination rates appear to have been on the rise in recent weeks.
“The sooner the person is vaccinated, the lower the level of viral transmission, the less likely they will continue to mutate,” said Deputy Dr. Steven Zersovsky. Director of the Army Health Center said at the end of February.
A new strain of COVID-19 has already occurred in South Africa and the UK. But military medical personnel are hopeful that current vaccines can fight those new strains. But if there was a problem, Walter Reed’s vaccine could prove it in time.
“We have designed and positioned this platform as the next generation of vaccines, paving the way for a universal vaccine to prevent not only the vaccine. But only current viruses But it can also resist future infections by stopping them before they can trigger another epidemic, ”Modjarrad said.
Pre-treatment studies indicated that SpFN induced a very strong antibody response in patients, suppressing the virus causing COVID-19 infection, as well as the three major SARS-CoV-2 strains and the SARS- virus. CoV-1
The Phase 1 study is being conducted at the Walter Reed Clinical Trial Center and will enroll 72 healthy adult volunteers aged 18-55.Participants will be randomized to the drug group. Pseudo or experimental group
The SpFN clinical trial was funded by the U.S. Army Medical Research and Development Agency.
The vaccine was developed by the Walter Reed Army Institute of Research with support from the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.